Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial

The Lancet

Volumn 385, Issue 9973, 2015, Pages 1075-1086

  Lawitz, Eric ^a   Gane, Edward ^b   Pearlman, Brian ^c   Tam, Edward ^d   Ghesquiere, Wayne ^e   Guyader, Dominique ^f   Alric, Laurent ^g   Bronowicki, Jean Pierre ^h   Lester, Laura ⁱ   Sievert, William ^j   Ghalib, Reem ^k   Balart, Luis ^l   Sund, Fredrik ^m   Lagging, Martin ⁿ   Dutko, Frank ^o   Shaughnessy, Melissa ^o   Hwang, Peggy ^o   Howe, Anita Y M ^o   Wahl, Janice ^o   Robertson, Michael ^o   Barr, Eliav ^o   Haber, Barbara ^o   more..

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Auckland Clinical Studies   (New Zealand)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d LAIR Centre   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MONASH UNIVERSITY   (Australia)

^k Texas Clinical Research Institute   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UPPSALA UNIVERSITY   (Sweden)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; INTERFERON; MACROGOL DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZOFURANS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUINOXALINES; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84925424553     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61795-5     Document Type: Article

References (30)

1. K Mohd Hanafiah, J Groeger, AD Flaxman, ST Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 2014 (accessed Sept 3, 2014)
3. E Gower, C Estes, S Hindman, K Razavi-Shearer, H Razavi Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 2014 10.1016/j.jhep.2014.07.027 published online July 30.
4. Centers for Disease Control and Prevention Recommendations for the indentification of chronic hepatitis C virus infection among persons born during 1945-1965 MMWR Morb Mortal Wkly Rep 61 2012 1 32
5. DB Rein, BD Smith, JS Wittenborn et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings Ann Intern Med 156 2012 263 270
6. AY Kim, S Onofrey, DR Church An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection J Infect Dis 207 suppl 1 2013 S1 S6
7. HH Thein, QL Yi, GJ Dore, MD Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
8. H Razavi, I Waked, C Sarrazin et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm J Viral Hepat 21 suppl 1 2014 34 59
9. H Razavi, AC Elkhoury, E Elbasha et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States Hepatology 57 2013 2164 2170
10. GL Davis, MJ Alter, H El Serag, T Poynard, LW Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
11. R Lozano, M Naghavi, K Foreman et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
12. BL Pearlman, N Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 2011 889 900
13. AJ van der Meer, BJ Veldt, JJ Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
14. E Lawitz, A Mangia, D Wyles et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
15. M Manns, P Marcellin, F Poordad et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
16. IM Jacobson, GJ Dore, GR Foster et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
17. S Zeuzem, T Berg, E Gane et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2014 430 441
18. A Osinusi, EG Meissner, YJ Lee et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
19. S Naggie, M Sulkowski, J Lalezari et al. Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV coinfected patients (PHOTON-1) Top Antivir Med 22 e-1 2014 14
20. MS Sulkowski, S Naggie, J Lalezari et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
21. C Hezode, H Fontaine, C Dorival et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 132 142
22. V Summa, SW Ludmerer, JA McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
23. CA Coburn, PT Meinke, W Chang et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 8 2013 1930 1940
24. F Lahser, R Liu, K Bystol et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons Hepatology 56 suppl S1 2012 236A
25. M Sulkowski, C Hezode, J Gerstoft et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 monoinfection and HIV/hepatitis C virus coinfection (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2014 published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61793-1
26. O Miettinen, M Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226
27. F Poordad, C Hezode, R Trinh et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
28. N Afdhal, KR Reddy, DR Nelson et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
29. E Lawitz, MS Sulkowski, R Ghalib et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 2014 published online July 28. http://dx.doi.org/10.1016/S0140-6736(14)61036-9
30. N Afdhal, S Zeuzem, P Kwo et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898